ArticleScientific reports2021
Matrine treatment reduces retinal ganglion cell apoptosis in experimental optic neuritis.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Phosphatase and tensin homolog: A potential target for therapeutic intervention in optic nerve regeneration.Neural regeneration research · 2026Article
- A sequential dual-drug delivery system for multi-target inhibition of subretinal fibrosis.Journal of nanobiotechnology · 2026Article
- Matrine Reduces Intraocular Pressure in Corticosteroid-Induced Ocular Hypertensive Mouse Eyes.Investigative ophthalmology & visual science · 2025Article
- Natural Matrine-Integrated Pollen Delivery Systems for Allergic Contact Dermatitis Treatment.Smart medicine · 2025Article
- In a novel autoimmune and high-pressure glaucoma model a complex immune response is induced.Frontiers in immunology · 2024Article
- Protective effect of baicalin on oxidative stress injury in retinal ganglion cells through the JAK/STAT signaling pathwayFrontiers in pharmacology · 2024Article
- Matrine exerts its neuroprotective effects by modulating multiple neuronal pathways.Metabolic brain disease · 2023Review
- Neurological disorders of COVID-19: insights to applications of natural products from plants and microorganisms.Archives of pharmacal research · 2022Review
- Research Advances on Matrine.Frontiers in chemistry · 2022Review
- Matrine promotes mitochondrial biosynthesis and reduces oxidative stress in experimental optic neuritis.Frontiers in pharmacology · 2022Article
- Ta-Xi-San Suppresses Atopic Dermatitis Involved in Multitarget Mechanism Using Experimental and Network Pharmacology Analysis.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory demyelination and axonal injury of the optic nerve are hallmarks of optic neuritis (ON), which often occurs in multiple sclerosis and is a major cause of visual disturbance in young adults. Although a high dose of corticosteroids can promote visual recovery, it cannot prevent permanent neuronal damage. Novel and effective therapies are thus required. Given the recently defined capacity of matrine (MAT), a quinolizidine alkaloid derived from the herb Radix Sophorae flavescens, in immunomodulation and neuroprotection, we tested in this study the effect of matrine on rats with experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. MAT administration, started at disease onset, significantly suppressed optic nerve infiltration and demyelination, with reduced numbers of Iba1
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.